{
  "docId": "019de070-7de1-7343-8d2f-5d51a9877c50",
  "docSlug": "ff3158b4501b6094038126272ca46097",
  "documentTitle": "BioAtla | IPO Presentation Deck | 31 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 6,
  "pageCount": 31,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a four-column layout to summarize key business drivers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-7de1-7343-8d2f-5d51a9877c50/6",
  "deckHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50",
  "deckJsonHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50.json",
  "deckAnchorHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "Proprietary CAB Antibody Platform; Significant Potential for Clinical Assets; Validating Global Collaboration; Broad Development Pipeline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64b254b5-4b80-4f37-a05c-f9f5fcad4637",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.28,
        "y": 0.45
      },
      "kind": "list",
      "text": "Two Phase 2 CAB ADCs; Phase 1 data show highly differentiated benefit/risk; Significant commercial potential; Initiated Phase 2 dosing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c295439-5547-477a-a81e-86a0c8d85ee3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.52,
        "y": 0.45
      },
      "kind": "list",
      "text": "CAB CTLA-4 BeiGene collaboration; CAB CTLA-4 could be integral to future I/O; $25 million in payments received; $225.5 million in potential milestones; Tiered royalties with highest tiers >20%",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4020171-e0c9-4744-9cd6-c00ade95432d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.76,
        "y": 0.45
      },
      "kind": "list",
      "text": "Other differentiated CAB molecules; Productive platform capable of bringing forward unique CAB molecules; Pipeline focus on naked antibodies, bispecifics and ADCs; Broad set of potential products",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd8c9dec-737f-4bb6-908b-5bbecbfb62b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "Advantages over traditional antibodies; Conditional and reversible binding; Increased drug exposure; Broader universe of tumor-specific antigen targets",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebb83879-7a4e-42f3-a89d-66f2b266f449",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1ADC (Antibody Drug Conjugate); 2Immuno-oncology (I/O)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55e33a5c-ab29-4524-afaf-c9468b14f116",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "BioAtla – Exceptional Opportunity to Create Value",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f01b3f7-cb07-42b0-99bf-e320d15370e7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 5,
      "beatId": "4611d736-bc8a-4474-8127-cea4a8259f0b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Team",
      "beatSlug": "sequoia-pitch-team",
      "evidence": "The document presents information on the management team on pages 5-6.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}